Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04232683 · ClinicalTrials.gov registry record · Early Phase 1

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

A Early Phase 1 study of Urinary Retention, sponsored by The Cleveland Clinic.

Active
Registry status
Early Phase 1
Development phase
100
Enrollment target
1
Study location

NCT04232683 is a Early Phase 1 study of Urinary Retention that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 100 participants, below the 131-participant average among 11 other Urinary Retention trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04232683, a Early Phase 1 study of Urinary Retention, is active but no longer recruiting, sponsored by The Cleveland Clinic.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Our hypothesis is that patients receiving preoperative Tamsulosin will have decrease rates of postoperative urinary retention (POUR) after surgery in females for pelvic floor disorders.

Conditions Studied

Interventions

  • DRUG Placebo oral tablet
  • DRUG Tamsulosin 0.4Mg Capsule

Study Locations (1)

Florida

  • Cleveland Clinic Florida - Weston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-12-18
Est. Completion 2025-12
Phase Early Phase 1

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT04232683

The ClinicalTrials.gov registry entry for NCT04232683 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 11 other Urinary Retention trials with a reported enrollment target (24% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Retention appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.

NCT04232683 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04232683 about?

NCT04232683 is a clinical study titled "Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders". Our hypothesis is that patients receiving preoperative Tamsulosin will have decrease rates of postoperative urinary retention (POUR) after surgery in females for pelvic floor disorders.

What is the current status of trial NCT04232683?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2019-12-18. Estimated completion is 2025-12.

What conditions does trial NCT04232683 study?

This clinical trial studies the following conditions: Urinary Retention.

What interventions are being tested in trial NCT04232683?

The interventions under investigation include: Placebo oral tablet (DRUG), Tamsulosin 0.4Mg Capsule (DRUG).

Who is sponsoring clinical trial NCT04232683?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04232683 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Retention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.